New web calculator to more accurately predict bowel cancer survival

June 16, 2017, University of Nottingham
cancer
Killer T cells surround a cancer cell. Credit: NIH

"How long do I have, doctor?" For many cancer patients, following the initial shock of their diagnosis, thoughts quickly turn to estimating how much precious time they have left with family and friends or whether certain treatments could prolong their life.

While current methods of estimating mortality can be crude, patients with bowel cancer could soon more accurately predict their chances of survival, thanks to a new web calculator 'QCancer Colorectal Survival' developed by academics at the University of Nottingham and medical software company ClinRisk Ltd.

The new tool, which can be accessed by doctors and patients alike, is intended to help people make more informed decisions around treatment and manage expectations following diagnosis.

Research to test the accuracy of the new calculator, published in the British Medical Journal (BMJ), has shown that the tool can reliably predict both absolute survival rates for men and women with colorectal cancer.

The calculator also allows patients to update their mortality risk based on how long they have survived following a diagnosis of cancer.

The tool was developed by Professors Julia Hippisley-Cox and Carol Coupland in the University's School of Medicine using the QResearch database, which gathers patient data from approximately 1500 general practices across England through the Egton Medical Information Systems (EMIS) clinical computer system.

Professor Hippisley-Cox said: "Current methods of estimating survival tend to be unreliable and sometimes patients can be given a fairly misleading and unnecessarily gloomy prognosis based only on the grade and stage of their cancer, only to find that in reality they live much longer than these crude predictions when other information is taken into account.

"The good news is that this new calculator which doctors and patients can access will offer a far more realistic estimate. We understand that not everyone will want to do this, of course, but some patients are very keen on this approach so it's an individual choice."

Current methods of predicting survival are based on simple averages based only on age or the grade and stage of the cancer in the wider population.

The new tool looks at a range of additional risk factors including the patient's, smoking history, body mass index, family history, other illnesses and treatments such as aspirin or statins as well as other information including whether they have had surgery or treatments such as chemotherapy to deliver a far more personalised prognosis.

The team used information from more than 44,000 patients from 947 practices to develop separate equations for men and women aged between 15 and 99 years old when diagnosed with bowel cancer.

They then tested the equations by using them retrospectively to predict the outcome at one year, five years and 10 years after diagnosis for 15,214 bowel from 305 different GP practices and 437,821 colorectal cancer patients from the national cancer registry.

The results indicated that the team has devised strong models for the prediction of cancer survival outcomes. They were also able to provide conditional survival estimates which show how mortality risks change over time, which are particularly important among patients where the initial prognosis is poor due to late stage disease.

For example, a 38-year-old woman with stage 4 advanced might decide to estimate her survival with or without surgery and chemotherapy to help assess the potential value of the treatment.

Using the web calculator, she could see that her chance of surviving for five-years without any would be just 6 per cent; with surgery that would increase to 23 per cent and with both treatments it would be 45 per cent.

This compares with the published five-year survival of 66 per cent based solely on her age or the eight per cent chance based solely on her cancer stage.

Assuming she has both treatments and survives for a year following her diagnosis, her five-year conditional survival would increase to 57 per cent.

Explore further: Screening gets top marks for picking up bowel cancer early

Related Stories

Screening gets top marks for picking up bowel cancer early

January 21, 2016
BOWEL cancer is more likely to be diagnosed at the earliest stage if it is picked up by screening, according to new figures released by Cancer Research UK and Public Health England's National Cancer Intelligence Network today ...

Specific immune cells predict bowel cancer outcomes

March 6, 2017
A pilot study by University of Otago researchers suggests that people with colorectal cancer that have a certain type of immune cell in their tumour may have increased survival rates.

Simple online tool to aid GPs in early ovarian cancer diagnosis

January 4, 2012
The lives of hundreds of women could be saved every year, thanks to a simple online calculator that could help GPs identify women most at risk of having ovarian cancer at a much earlier stage.

Family history of bowel cancer increases odds of survival

March 20, 2013
A new study that combines genetic information on bowel cancer with NHS patient outcome data has found a link between family history of the disease and a better chance of survival, published in the British Journal of Cancer.

Findings suggest overuse of chemotherapy among younger patients with colon cancer

January 25, 2017
Young and middle-aged patients with colon cancer are nearly 2 to 8 times more likely to receive postoperative chemotherapy than older patients, yet study results suggest no added survival benefit for these patients, according ...

Older people at higher risk of emergency cancer diagnosis

April 1, 2015
People over 60 are at higher risk of being diagnosed with lung or bowel cancer as an emergency in hospital than younger people, according to a Cancer Research UK-supported report , published today by BMJ Open.

Recommended for you

Stem cell vaccine immunizes lab mice against multiple cancers

February 15, 2018
Stanford University researchers report that injecting mice with inactivated induced pluripotent stem cells (iPSCs) launched a strong immune response against breast, lung, and skin cancers. The vaccine also prevented relapses ...

Induced pluripotent stem cells could serve as cancer vaccine, researchers say

February 15, 2018
Induced pluripotent stem cells, or iPS cells, are a keystone of regenerative medicine. Outside the body, they can be coaxed to become many different types of cells and tissues that can help repair damage due to trauma or ...

Team paves the way to the use of immunotherapy to treat aggressive colon tumors

February 15, 2018
In a short space of time, immunotherapy against cancer cells has become a powerful approach to treat cancers such as melanoma and lung cancer. However, to date, most colon tumours appeared to be unresponsive to this kind ...

Can our genes help predict how women respond to ovarian cancer treatment?

February 15, 2018
Research has identified gene variants that play a significant role in how women with ovarian cancer process chemotherapy.

First comparison of common breast cancer tests finds varied accuracy of predictions

February 15, 2018
Commercially-available prognostic breast cancer tests show significant variation in their abilities to predict disease recurrence, according to a study led by Queen Mary University of London of nearly 800 postmenopausal women.

Catching up to brain cancer: Researchers develop accurate model of how aggressive cancer cells move and spread

February 15, 2018
A brief chat at a Faculty Senate meeting put two University of Delaware researchers onto an idea that could be of great value to cancer researchers.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.